kabutan

Kubota Pharma, Last Fiscal Year's Undisclosed Net Income to Narrow

Wed Feb 12, 2025 3:30 pm JST Revision

4596 Kubota Pharmaceutical Holdings Co., Ltd. 【IFRS】

Guidance Update Report

Kubota Pharmaceutical Holdings Co., Ltd. <4596> [TSE Growth] announced a previously undisclosed earnings forecast after the market closed on February 12th (15:30). The consolidated net loss for the fiscal year ending December 2024 is expected to further decrease to loss of 1.33 billion yen (compared to a loss of 1.49 billion yen in the previous period).

Kabutan News

Guidance Update

Second Half Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Jul - Dec, 2024 Prev 0 Feb 14, 2024 IFRS
Jul - Dec, 2024 New 17 -614 -664 -664 -11.8 0 Feb 12, 2025 IFRS
Revision Rate

Full Year Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec, 2024 Prev 0 Feb 14, 2024 IFRS
Dec, 2024 New 27 -1,289 -1,333 -1,333 -23.7 0 Feb 12, 2025 IFRS
Revision Rate

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Jul - Dec, 2023 23 -757 -745 -745 -13.4 0 Feb 14, 2024 IFRS
Jul - Dec, 2024 Guidance 17 -614 -664 -664 -11.8 0 Feb 12, 2025 IFRS
YoY -26.1% +18.9% +10.9% +10.9% +12.1%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec, 2022 8 -2,038 -2,016 -2,016 -40.9 0 Feb 14, 2023 IFRS
Dec, 2023 40 -1,504 -1,490 -1,490 -26.8 0 Feb 14, 2024 IFRS
Dec, 2024 Guidance 27 -1,289 -1,333 -1,333 -23.7 0 Feb 12, 2025 IFRS
YoY -32.5% +14.3% +10.5% +10.5% +11.7%

Related Articles